Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

June 3, 2015

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Glioma
Interventions
DRUG

Rhenium Liposome Treatment

At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.

Trial Locations (3)

11030

RECRUITING

Northshore University Hospital, Manhasset

75390

RECRUITING

UT Southwestern Medical Center, Dallas

78229

RECRUITING

The Cancer Therapy and Research Center at UTHSCSA, San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Plus Therapeutics

INDUSTRY

NCT01906385 - Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) | Biotech Hunter | Biotech Hunter